skip to content


Issue No. 4 | February 1, 2013

News and Features

Correction to Dosing Recommendation in the Perinatal Guidelines Clarified

A recent change to the Perinatal Guidelines was further clarified on January 29, 2013. To see the clarification regarding the nevirapine (NVP) dosing recommendation in Table 9. Recommended Neonatal Dosing for Prevention of Mother-to-Child Transmission of HIV, please view the correction notice.

FDA Updates Complera Labeling with New Indication and Clinical Trial Information

“On January 25, 2013, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) package insert. The major changes include restricting the indication to treatment-naïve adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL, updating the package insert with the 96 week results from the Phase 3 trials and adding a new Contraindication and new Warning and Precaution for hepatotoxicity.”

More information is available:

New Publications Available from CDC

The Centers for Disease Control and Prevention (CDC) recently issued the following three publications: